Alternative Therapy Sparks Hope for Patients with Lupus

The efficiency of the Rituxan treatment, in both refractory or relapsing cases, was demonstrated in an open label study that showed various promising systematic reviews carried out to a large audience. For instance, a 188-patient study in victims with refractory SLE demonstrates a clinical response in 91 percent of the treated parents while another review that summarizes 26 published reports in 300 patients concludes that complete or partial renal responses were met in over 85 percent of the patients with Class III and 76 percent of patients with class IV and 67 percent of patients with class V in a median period of over 60 weeks.